Abstract. AT-101, an orally available and well-tolerated natural pan-Bcl-2 family protein inhibitor, has been reported to be effective against a variety of cancers. However, the mechanisms whereby AT-101 exhibits anticancer activity have not been fully elucidated. In this study, we demonstrated that AT-101 reduced the cell viability of human esophageal cancer cells by inducing G 1 /G 0 phase arrest and apoptosis. Apoptotic cell death occurred later than cell cycle arrest, as evidenced by an increase in the proportion of Annexin V-positive cells and cleaved caspase-3, -9 and PARP protein levels. AT-101 markedly downregulated the protein levels of phospho-retinoblastoma (Ser 780) and cyclin D1, whereas it elevated protein levels of p53 and p21 Waf1/Cip1 , contributing to the inhibition of cell cycle progression. Moreover, AT-101 substantially reduced β-catenin expression. XAV-939, a small molecule that inhibits the Wnt/β-catenin signaling pathway by facilitating β-catenin degradation, lowered β-catenin and cyclin D1 protein expression to an extent similar to AT-101. XAV-939 alone resulted in G 1 /G 0 phase arrest and further induced cell cycle arrest in combination with AT-101, suggesting that the β-catenin/cyclin D1 signaling pathway mediated, at least in part, the cell cycle arrest induced by AT-101. The present study may shed new light on the anticancer activity of AT-101 in relation to cell cycle arrest as well as apoptosis in human esophageal cancer cells.
Introduction
Esophageal cancer is the eighth most commonly diagnosed type of cancer and results in more than 400,000 deaths worldwide annually (1, 2) . The prognosis of this malignancy remains poor due to the absence of targeted therapeutics and resistance to conventional DNA-damaging agents. Evading apoptosis, a hallmark of cancer, is a major cause of tumor progression, resistance to chemotherapy and treatment failure (3) . Many signaling pathways converge on Bcl-2 family members to regulate the induction of apoptosis. In cancer, initiation of apoptosis is hard to achieve due to the disturbed balance between anti-apoptotic members (Bcl-2/Bcl-xL/Mcl-1/A1/Bcl-w) and pro-apoptotic members that include multidomain Bak, Bax and the BH3-only proteins (Bad/Bim/Bid/Puma/Noxa) (4, 5) . The development of BH3 mimetics, which inhibit anti-apoptotic Bcl-2 family members, appears to be an attractive strategy for restoring the apoptotic response.
High Bcl-2 expression has been reported to be correlated with a low apoptotic index and is associated with the histopathological grade in human esophageal carcinomas (6) . By contrast, low Bax expression was found to be negatively associated with the survival of patients with locally advanced esophageal cancer (7) . Furthermore, a recent study demonstrated that the Bcl-2 protein level was abnormally elevated with the progression of cancer in carcinogen-induced esophageal cancer in rats (8) . These findings suggest that the inhibition of anti-apoptotic Bcl-2 proteins holds promise as a therapeutic strategy for esophageal cancer.
AT-101, the R-(-) enantiomer of gossypol acetic acid, is a polyphenolic compound derived from the cottonseed plant (9) . AT-101 is capable of inhibiting the anti-apoptotic (10) . The therapeutic potential against multiple cancers of AT-101 alone or in combination with standard anticancer therapies has been widely reported preclinically (11) (12) (13) (14) (15) (16) . Notably, the preliminary activity of AT-101 was also observed in patients with esophageal cancer in a phase I study (17). However, the mechanisms underlying the anticancer activity of AT-101 in esophageal cancer remain poorly understood. Our study aimed to investigate the effects of AT-101 on cell viability in relation to cell cycle progression and apoptosis in esophageal cancer cells, and explore the signaling pathways underlying the effects of AT-101 on cell cycle progression. We hope that this study will shed new light on the anticancer mechanism of AT-101.
Materials and methods
Reagents. AT-101 was purchased from Selleck Chemicals (Houston, TX, USA 2 , while CaES-17 cells were grown in MEM (Corning Cellgro, Corning, NY, USA). Both media were supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin G and 100 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.). Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).
EC109 and CaES-17 cells were plated into 96-well plates and allowed to adhere overnight. Cells were treated with various concentrations of AT-101 for 48 h. After 48 h, MTT solution was added at a final concentration of 0.5 mg/ml, and the cells were incubated for a further 4 h. The absorbance of the colored formazan product was determined at 570 nm using a multiwall plate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Cell cycle analysis. After AT-101 treatment, EC109 and CaES-17 cells were collected, washed twice with phosphate-buffered saline (PBS) and fixed with ice-cold 70% ethanol in PBS for at least 18 h. Cells were then stained with 50 µg/ml propidium iodide (PI; Sigma-Aldrich; Merck KGaA) and 0.5 µg/ml RNase-A (Sigma-Aldrich; Merck KGaA) at 37˚C for 30 min and analyzed by BD FACSCanto™ II flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). Cell cycle was analyzed based on the DNA contents using FlowJo 7.6 software (Treestar, Inc., Ashland, OR, USA).
Apoptosis assay. After AT-101 treatment, adherent cells were harvested through trypsinization (Invitrogen; Thermo Fisher Scientific, Inc.) and then combined with unattached cells. Apoptosis was determined using the Fluorescein Isothiocyanate (FITC) Annexin V Apoptosis Detection Kit (BD Biosciences) according to the manufacturer's instructions. The extent of apoptosis was quantified as the proportion of Annexin V-positive cells.
Western blot analysis. Cells were lysed in radioimmunoprecipitation buffer containing protease inhibitors and phosphatase inhibitor cocktail (Sigma-Aldrich; Merck KGaA). Equal amounts of protein were subjected to SDS-PAGE and then transferred to polyvinylidene fluoride membranes (Roche Diagnostics, Indianapolis, IN, USA). The membranes were blocked with 5% skimmed milk solution for 1 h and then probed with the indicated primary antibodies overnight at 4˚C and secondary horseradish peroxidase-conjugated antibodies for 1 h at room temperature. Chemiluminescent signals were then developed with Lumiglo reagent (Cell Signaling Technology, Inc.) and exposed to X-ray film (Fujifilm Europe GmbH). Quantification of protein in luminescent bands was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Inhibition and activation assays. EC109 and CaES-17 cells (1x10 5 /dish) were plated into 6-well plates and allowed to adhere overnight. Cells were treated with AT-101 (2 µM) alone or in combination with the β-catenin inhibitor XAV-939 (5 µM) or β-catenin activator WAY-262611 (5 µM) for 48 h. The untreated cells were used as negative control. After drug treatment, cells were collected for conducting western blot analysis or subjected to cell cycle analysis. The gray level of the band from western blot was analyzed by ImageJ software (National Institutes of Health).
Statistical analysis. All the experiments described were independently repeated at least three times. The data are representative of multiple experiments and expressed as the mean ± SD. The statistical analysis was performed using one-way ANOVA followed by Tukey's post hoc test. P-values were defined as * P<0.05, ** P<0.01, *** P<0.001 and NS, not significant (as shown in the figures). In addition, exposure to AT-101 for 48 h increased the number of cells in the sub-G 1 phase in both cell lines, which is indicative of apoptotic cells (Fig. 2) .
Results

AT-101 reduces
AT-101 induces apoptosis. In order to further confirm the pro-apoptotic action of AT-101, flow cytometry-based FITC Annexin V/PI double staining was performed. As shown in Fig. 3A, a 12 -or 24-h treatment of AT-101 (2 µM) did not significantly increase the proportion of Annexin V-positive cells. However, when exposure time was prolonged to 48 h, AT-101 significantly elevated the cell population with Annexin V-positive staining. The pro-apoptotic effect of AT-101 was also observed in CaES-17 cells. Staurosporine (0.1 µM) was used as a positive control for the induction of apoptosis (Fig. 3A) . Moreover, AT-101 exposure for 48 h substantially induced cleavage of caspase-3, caspase-9 and PARP in EC109 and CaES-17 cells, whereas a 12-or 24-h treatment did not exert such an effect (Fig. 3B) . 
AT-101 regulates the expression of cell cycle regulators.
Given the ability of AT-101 to arrest cells in the G 1 /G 0 -phase, we further examined the expression level of the regulatory proteins involved in G 1 -to-S transition in EC109 and CaES-17 cells treated with AT-101. In this respect, there was no significant change in the expression of CDKs, including CDK2, CDK4 and CDK6, whereas cyclin D1 expression was substantially decreased after AT-101 treatment. AT-101 obviously increased the phosphorylation of p53 at Ser15 as well as the p53 protein level. Although the expression of the CDK inhibitor p27 kip1 was not affected in response to AT-101 exposure, the protein level of another CDK inhibitor p21
Waf1/Cip1 was substantially elevated within 12 h and went back to basal level after 24 h treatment. Moreover, AT-101 did not alter the total Rb protein levels, whereas it substantially reduced the phosphorylation of Rb at Ser780 (Fig. 4) .
AT-101 induces G 1 /G 0 phase arrest via β-catenin/cyclin D1
signaling. Cyclin D1 plays a critical role in G 1 -to-S transition. Thus, we further determined the mechanisms whereby AT-101 decreases the protein level of cyclin D1. In this scenario, AT-101 dramatically decreased the protein expression of β-catenin, with a concomitant increase in phosphorylated β-catenin at Ser33, Ser37 and Thr41, which facilitated its degradation by GSK-3β (Fig. 5A) . Notably, XAV-939, a small molecule that inhibits the Wnt/β-catenin signaling pathway by stimulating β-catenin degradation, decreased β-catenin as well as cyclin D1 protein expression to an extent analogous to AT-101 (Fig. 5B) . Moreover, both AT-101 and XAV-939 significantly arrested cells in the G 1 /G 0 phase. The combination of these two compounds further induced G 1 /G 0 phase arrest (Fig. 5C) . On the contrary, the selective β-catenin agonist WAY-262611 recovered the decreased expression levels of β-catenin and cyclin D1 as well as G 1 /G 0 phase arrest caused by AT-101 ( Fig. 5D and E) . These findings suggest that AT-101 may induce G 1 /G 0 phase arrest through β-catenin/cyclin D1 signaling.
Discussion
Esophageal cancer is a lethal disease with a dismal prognosis. The therapeutic benefits for patients with esophageal cancer are still limited after decades of research. New therapies to improve patient outcome are urgently needed. In this study, we demonstrated that the Bcl-2 inhibitor AT-101 strongly induced G 1 /G 0 phase arrest followed by apoptosis in human esophageal cancer cell lines. Furthermore, the β-catenin/cyclin D1 pathway contributed to its cell cycle arresting activity.
There is accumulating evidence showing that the antitumor activity of Bcl-2 inhibitors is not limited to the initiation of apoptosis, despite the fact that Bcl-2 inhibitors were originally designed to induce apoptosis. In this regard, Bcl-2 inhibitors have been reported to block cell cycle progression (18, 19) , regulate autophagy (20) (21) (22) and inhibit tumor stemness (23) . It has been showed that AT-101 significantly suppressed the hedgehog (Hh) signaling pathway and suppressed the growth of Hh-driven cancer in vitro and in vivo (24) . Moreover, it was reported that AT-101 induced autophagy in apoptosis-resistant prostate cancer by modulating Bcl-2-Beclin1 interaction in the endoplasmic reticulum (25) . In addition, gossypol induced apoptosis via a reactive oxygen species-independent mitochondrial pathway (26). Moon et al (27) reported that gossypol suppressed NF-κB activity and induced apoptosis in human leukemia U937 cells. Our data showed that AT-101 reduced cell viability in esophageal cancer cells by inducing G 1 /G 0 phase arrest and apoptosis. AT-101 significantly increased the G 1 /G 0 cell population following a 24-h treatment. However, AT-101 induced obvious apoptosis after 48 h treatment, evidenced by an increase in Annexin V-positive cells as well as cleavage of caspase-3, caspase-9 and PARP. Notably, AT-101 obviously decreased the expression of Mcl-1 and Bcl-2 both in EC109 and CaES-17 cells after a 48-h exposure, which may also contribute to its pro-apoptotic action (data not shown). Although cell cycle progression blockage may activate signaling pathways leading to apoptosis (28) , whether G 1 /G 0 phase arrest induced by AT-101 has a potential connection with apoptosis occurring later, warrants further investigation. On the basis of the data presented in this study, AT-101-induced cell cycle arrest results in its anticancer activity and occurs prior to apoptosis.
In view of the G 1 /G 0 phase arrest being induced by AT-101, we further explored the effect of AT-101 on the molecular pathways mediating G 1 to S phase transition. Activity of CDKs, critical master regulators of the cell cycle, is regulated by the abundance of their cyclin partners and by association with endogenous CDK inhibitors. The active CDK-cyclin complex targets the Rb protein for phosphorylation, which is followed by the release of E2F transcription factors that activate G 1 /S-phase gene expression (29) (30) (31) . In our study, AT-101 treatment did not affect the CDK2/4/6 protein levels but significantly decreased cyclin D1 expression. Furthermore, AT-101 substantially increased the CDK inhibitor p21 , p-Rb (Ser780) expression was downregulated after cells were treated with AT-101, whereas the protein level of total Rb remained quite stable. Notably, we also observed an obvious increase in the protein level of p53 and p-p53 (Ser15) in response to AT-101 treatment. Given the fact that p53 Ser15 phosphorylation has been reported to promote both the accumulation and activation of p53 (32), we proposed that AT-101-induced phosphorylation of p53 could contribute to the increased protein level of p53. The tumor suppressor protein p53 plays a key role in both cell cycle arrest and apoptosis. In addition, p21
Waf1/Cip1 is a direct transcription target of p53 (33) . These findings suggest that elevated protein expression of p53 in response to AT-101 exposure could take part in both apoptosis and G 1 /G 0 phase arrest by increasing the p21 Waf1/Cip1 protein level. The cyclin D1 gene has been demonstrated to be a direct target for transactivation via the β-catenin/LEF-1 pathway through a LEF-1 binding site in the cyclin D1 promoter (34) . Thus, we determined whether the increased cyclin D1 protein level in response to AT-101 treatment was regulated by β-catenin. In this respect, AT-101 substantially lowered protein expression of β-catenin, which could be due to the acceleration of its degradation, evidenced by the increase of p-β-catenin at Ser33, Ser37 and Thr41. Moreover, the β-catenin inhibitor XAV-939 suppressed the protein level of β-catenin and cyclin D1, mimicking the effect of AT-101. Similarly, XAV-939 treatment induced cell cycle arrest in G 1 /G 0 phase alone and further arrested cells in combination with AT-101. These findings suggest that the suppression of β-catenin by AT-101 could contribute to the downregulation of cyclin D1, leading to G 1 /G 0 cell cycle phase arrest.
In conclusion, our study showed that the Bcl-2 inhibitor AT-101 induces G 1 /G 0 phase arrest prior to apoptosis in human esophageal cancer cells. Furthermore, AT-101 blocks cell cycle progression by regulating a variety of proteins that mediate G 1 to S phase transition. Of note, our previous studies have demonstrated that other Bcl-2 inhibitors with different chemical structures from AT-101 exhibited a similar pattern on cell cycle progression as well as apoptosis (18, 20) . Thus, we propose that G 1 /G 0 phase arrest might not be a unique cellular response to AT-101 but instead a common response to Bcl-2 inhibitors, suggesting a potential link between Bcl-2 family members and cell cycle progression. In summary, our findings may shed new light on the anticancer activity of AT-101 and its potential application for patients with esophageal cancer.
